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Abstract
Mechanisms of protein misfolding are of increasing interest in the aetiology of neurodegenerative diseases characterized by
protein aggregation and tangles including Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease (AD), Parkinson’s disease
(PD), Lewy Body Dementia (LBD), and Progressive Supranuclear Palsy (PSP). Some forms of neurodegenerative illness are
associated with mutations in genes which control assembly of disease related proteins. For example, the mouse sticky
mutation sti, which results in undetected mischarging of tRNAAla with serine resulting in the substitution of serine for
alanine in proteins causes cerebellar Purkinje cell loss and ataxia in laboratory animals. Replacement of serine 422 with
glutamic acid in tau increases the propensity of tau aggregation associated with neurodegeneration. However, the
possibility that environmental factors can trigger abnormal folding in proteins remains relatively unexplored. We here report
that a non-protein amino acid, b-N-methylamino-L-alanine (BMAA), can be misincorporated in place of L-serine into human
proteins. We also report that this misincorporation can be inhibited by L-serine. Misincorporation of BMAA into human
neuroproteins may shed light on putative associations between human exposure to BMAA produced by cyanobacteria and
an increased incidence of ALS.
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Introduction
Protein translation is a highly efficient and accurate process for
assembling the 20 standard amino acids into proteins. Error rates
in translation are relatively rare (1 in 103 to 104) and rely on the
ability of the system to discriminate between the 20 protein (or
canonical) amino acids [1]. However such rare errors which result
in the mischarging of tRNA by the wrong amino acid can result in
misfolded or truncated proteins, and subsequent cell damage, such
as in the sti (sticky) mutation in mice where serine is substituted for
alanine, resulting in neurodegeneration [2]. A mutation causing
glutamic acid to be substituted for serine at position 422 in tau
increases the likelihood of tau aggregation associated with
neurodegeneration [3].
During protein translation the genetic code is interpreted from
information contained in the nucleic acid sequence in messenger
RNA (mRNA) into the primary amino acid sequence of a
polypeptide chain. Fidelity of protein synthesis, at the translational
level, relies on the specificity of protein amino acid and cognate
tRNA recognition by tRNA synthetases. In certain cases when two
protein amino acids have a similar structure, a proofreading step
checks the structural fidelity of an amino acid to the catalytic site of
the tRNA synthetase and the bond is hydrolyzed if the wrong
amino acid is attached [1]. Hundreds of non-protein amino acids
exist; many occur naturally in plants, some are produced in vivo
from amino acid oxidation, and others are synthetically produced
[3–8]. Non-protein amino acids that are close structural analogues
of any of the 20 protein amino acids can bind to an amino acid-
tRNA synthetase and become mistakenly peptide bonded into a
polypeptide chain [8]. In order to be incorporated into proteins,
non-protein amino acids have to be present in the cell at sufficient
concentrations to successfully compete with the protein amino
acid. Examples of non-protein amino acids that are misincorpo-
rated into proteins include canavanine and 3,4 dihydroxyphenyl-
alanine (L-dopa) [6,8–10].
b-N-methylamino-L-alanine (BMAA) has been found to be
associated with proteins in cyanobacteria and other organisms
[11–13]. The possibility that BMAA is misincorporated into
proteins was bolstered by a study in which autoradiographic
analysis was performed on mice after a single injection of 3H-
BMAA producing ‘‘a distribution pattern similar to that of a
protein forming amino acid’’ [14]. 3H-BMAA uptake was
demonstrated in tissues with high levels of protein synthesis, and
radioactivity was maintained in the tissue after acid extraction
[14]. These data are consistent with incorporation of BMAA by
protein synthesis.
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Materials and Methods
MRC-5 cells, a human lung fibroblast cell line, were from
American Tissue and Cell Culture (ATCC, Virginia, USA). SH-
SY5Y cells, a human neuroblastoma cell line, were from the
European Collection of Cell Cultures (ECACC, Public Health
England, UK). Human umbilical vein endothelial cells (HUVECs)
were obtained from umbilical cords as described previously [15].
L-BMAA [methyl-3H] (3H-BMAA) (80 Ci/mmol, 0.5 m Ci/mL)
was obtained from American Radiolabeled Chemicals and L-[4,5-
3H]leucine (139 Ci/mmol and 1 mCi/mmol) was purchased from
Amersham. Dulbecco’s modification of Eagle’s minimum essential
medium (DMEM) and HAMS F12 were from JRH Biosciences,
(Lenexa, Kansans, USA). BMAA, dithiothreitol (DTT), all amino
acids, cycloheximide (CHX), sodium dodecyl sulphate (SDS) and
pronase E (protease from Streptomyces griseus) were from Sigma
Chemical Co. (Sigma-Aldrich, Castle Hill, NSW, Australia).
Bicinchoninic acid (BCA) assay protein reagent was from Pierce
Biotechnology (Rockford, IL, USA). The BD PharminigenTM
Annexin V-FITC apoptosis detection kit was from BD Biosciences
(Sydney, Australia). Water was from a Milli Q 4 stage system
(Millipore-Waters, Lane Cove NSW, Australia). Other chemicals
and solvents were AR grade.
Cell Culture
MRC-5 cells, (passage number 14–19), and SH-SY5Y cells,
(passage number 30–32), were maintained in DMEM, or DMEM/
Hams F12 respectively containing 10 % fetal bovine serum (FBS),
4 mM L-glutamine, 100 U/mL penicillin, and 100 mg/mL
streptomycin at 37uC in a humidified atmosphere of 5% CO2
and 95% air. HUVECs were harvested enzymatically with type II
collagenase (Sigma-Aldrich) under sterile conditions as described
by Minter [16] and established as primary cell cultures in M199
(Trace Biosciences, Sydney, Australia) containing 20% FBS,
4 mM L-glutamine, 0.5% endothelial cell growth promoter,
100 U/mL penicillin, and 100 mg/mL streptomycin. All media
were prepared with endotoxin-free water (Baxter) and filtered with
Zetapore filters (Cuno Life Sciences Division). Cells were seeded at
36105 cells per well in 6 well plates and allowed to adhere
overnight (16 hours) before treatment.
Studies Examining Incorporation of BMAA into Proteins
and Inhibition of Incorporation by Cycloheximide and
Amino Acids
MRC-5 cells were incubated with 3H-BMAA (31.25 nM) in
Hank’s buffered salt solution (HBSS) containing 10% FBS. After 2,
4, and 16 hours, cells were washed three times in phosphate
buffered saline (PBS) supplemented with 10% FBS and lysed by
freeze thawing three times in Triton X-100 (0.1%). The protein
concentration in the lysate was determined using the BCA assay
[17], radiolabel in the cell lysate quantified by liquid scintillation
counting (LSC) and the amount of radiolabel present in proteins
expressed as disintegrations per minute (DPM) per cell protein.
Cell proteins were then isolated by trichloroacetic acid (TCA)
(10%) precipitation washed three times in TCA (10%), and
dissolved in formic acid (neat). To determine if incorporation of
radiolabel into proteins was protein synthesis dependent, MRC-5,
SH-SY5Y and HUVEC cells were incubated with 3H-BMAA
(31.25 nM) with or without CHX 2 mg/ml for 16 hours. The
amount of radiolabel present in cell proteins in the CHX-treated
cultures was expressed relative to that of control cultures, which
was set at 100%. Parallel cultures of MRC-5 cells were incubated
with 3H-leucine (41 nM) with or without CHX 2 mg/ml under
identical culture conditions and processed as before.
To examine the ability of individual amino acids to reduce
incorporation or radiolabel into proteins, MRC-5 cells were
incubated with 3H-BMAA (31.25 nM) for 16 hours in the presence
of individual amino acids (250 mM) and the radiolabel present in
the cell proteins assessed as before. All of the 20 protein amino
acids (L-isomers) were examined individually in triplicate cell
cultures. To confirm that L-serine had an inhibitory effect on
incorporation of radiolabel into proteins, MRC-5 cells were
incubated with 3H-BMAA (31.25 nM) for 16 hours in the presence
of L-serine (0, 50, 100 and 250 mM) and in a separate experiment
with 250 mM L-serine and D-serine. Incorporation of radiolabel
was determined relative to cells incubated in medium containing
no serine. MRC-5 cells were then incubated with 3H-BMAA
(31.25 nM) for 16 hours in HBSS alone, HBSS containing all 20
protein amino acids (400 mM) or 19 protein amino acids expect L-
serine and radiolabel in cell protein assessed as before.
Recovery of Radiolabel from Cell Proteins Generated by
Incubating SH-SY5Y Cells with 3H-BMAA
SH-SY5Y cells were incubated with 3H-BMAA (31.25 nM) for
24 hours and cell proteins isolated by TCA (10%) precipitation.
Proteins were washed three times in TCA (10%), rinsed in ice-cold
acetone and re-dissolved in PBS. The amount of radiolabel
released from the proteins (i.e. not TCA precipitable) after
incubation at 37uC with DTT (1 mM) and SDS (2%) with DTT
(DTT/SDS) was determined by LSC. Cell proteins were also
incubated with pronase (2 mg/mL) for 48 hours in 100 mM Tris
hydrochloric acid (HCl) buffer pH 8 containing 20 mM CaCl2 at
37uC or in HCl (12 M) for 12 hours and the release of radiolabel
quantified relative to that of the buffer alone (for pronase) or water
(for HCl). All protein samples were processed in triplicate.
Recovery of Incorporated BMAA from Proteins Following
Hydrolysis
After incubation with 3H-BMAA or non-labeled BMAA, cells
were washed three times with PBS, lysed by freeze thawing in
Triton X-100 (0.1%) and cell proteins precipitated in TCA (10%).
Protein pellets were washed three times with TCA (10%) and
hydrolyzed in boiling 6 M HCl at 110uC for 16 hours as
previously described [18]. Protein pellets were freeze-dried and
reconstituted in 20 mM HCl. Particulates were removed by
centrifugation through 0.22 mM membranes. Non-labeled BMAA
was detected in total lysate by derivatization with 6-aminoquino-
lyl-N-hydroxysuccinimidyl carbamate (AQC, Waters Corporation,
Australia) and quantified by a validated liquid chromatography
tandem mass spectrometry (LC/MS/MS) method (see below). 3H-
BMAA was quantified as described previously [19].
Liquid Chromatography Tandem Mass Spectrometry
Hydrolyzed samples as above were resuspended in 20 mMHCl.
All samples were appropriately diluted for a balanced reaction
before being derivatized with AQC and checked by dilution series
and by evaluating double derivatized lysine relative to single
derivatized lysine. Samples were analyzed using a triple quadru-
pole, heated electrospray ionization tandem mass spectrometer
(HESI-MS/MS) instrument (Thermo Scientific Finnigan TSQ
Quantum UltraAM, San Jose, CA) after separation with an Ultra
High Pressure Liquid Chromatography (Waters Acquity-UHPLC)
system with a Binary Solvent Manager, Sample Manager and a
Waters AccQTag Ultra C18 column (part# 186003837,
2.16100 mm) at 55uC.
Separation was achieved using gradient elution at 0.65 ml/min
in aqueous 0.1% (v/v) formic acid (Eluent A) and 0.1% (v/v)
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formic acid in acetonitrile (Eluent B): 0.0 min= 99.1% A;
0.5 min= 99.1% A curve 6; 2 min= 95% A curve 6;
3 min= 95% A curve 6; 5.5 min= 90% A curve 8; 6 min= 15%
A curve 6; 6.5 min= 15% A curve 6; 6.6 min= 99.1% A curve 6;
8 min= 99.1% A curve 6. Nitrogen gas was supplied to the HESI
probe with a nebulizing pressure of 40 psi and a vaporization
temperature of 400uC. The tandem mass spectrometer was
operated under the following conditions: the capillary temperature
was set at 270uC, capillary offset of 35, tube lens offset of 110,
auxiliary gas pressure of 35, spray voltage 3500, source collision
energy of 0, and multiplier voltage of -1654. A divert valve was
used to deflect flow during the beginning and end of the gradient.
The second quadrupole was pressurized to 1.0 mTorr with 100%
argon. Product-ion analysis of BMAA used m/z 459 as the
precursor ion for collision-induced dissociation (CID) and thereby
all other ions were excluded in the first quadrupole. Further two-
step mass filtering was performed during selective reaction
monitoring (SRM) of BMAA after CID in the second quadrupole,
monitoring the following transitions: m/z 459 to 119, collision
energy (CE) 21 eV; m/z 459 to 171 CE 38 eV; m/z 459 to 188 CE
38 eV; m/z 459 to 214 CE 35 eV; m/z 459 to 258 CE 21 eV; and
m/z 459 to 289 CE 17 eV. The resultant product ions were
detected within the third quadrupole and their relative abundanc-
es were quantified. Chromatographic separation with unique
retention times, and unique product ions, and ion ratios confirmed
the identification of BMAA relative to any possible isomers [2,4-
diaminobutryic acid (DAB) and N-(2-aminoethyl)glycine][20].
Detection limits (LOD) and limits of quantification (LOQ) of
BMAA on the LC-MS/MS were determined experimentally by
injecting a dilution series of authenticated stock solutions at 4
concentrations (0.015, 0.15, 1.5, 15 mg/l). The EPA Method
Detection Level (MDL) was used which defines the LOD as the
minimum concentration of substance that can be measured and
reported with 99% confidence that the analyte concentration is
greater than zero. The MDL (48 femtomoles) was calculated using
the standard deviation of replicates multiplied by the t statistic with
a=0.01 and n= 1 degrees of freedom. The LOQ (0.48 picomoles)
was calculated by multiplying the MDL by 10. For validation
purposes, the standard curve for BMAA had the following
equation: f(x) = 31887463155463x + 19212, r2 = 0.99). The intra-
day precisions for the transition m/z 459 to 171 (n= 8) were
evaluated according to the percent relative standard deviation
(RSD) for peak area (mean 3018539, 6.3 RSD) and retention time
(mean 4.98 min, 0.21 min RSD). The intra-day single reaction
monitoring ratio (SRM) of m/z 459 to 289 and m/z 459 to119
relative to m/z 459 to 171 (n= 9) was 29.5 +/2 2.0 SD and 18.4
+/2 1.2 SD respectively. The inter-day precision for the transition
m/z 459 to 171 (n= 8) was evaluated for peak area (mean
2484745, 5.0 RSD) and retention time (mean 5.02 min, 0.26 min
RSD). The inter-day SRM ratio of m/z 459 to m/z 289 and m/z
459 to m/z 119 relative to m/z 459 to m/z 171 (n= 21) was 30.7 +/
2 2.4 SD and 17.2 +/2 1.5 SD respectively. Samples were run
blinded to the instrument operator as well as the lab staff.
Autofluorescent Imaging of Cells
MRC-5 cells were incubated in DMEM supplemented with
300 mM BMAA in the presence or absence of 300 mM L-serine for
96 hours with daily medium changes. Cellular autofluorescence
was visualized using an inverted fluorescent microscope (Olympus
IX71) as described previously [21].
Lactate Dehydrogenase (LDH) Assay
LDH release from cells was determined as described previously
[22].
Binding of Annexin V to Phosphatidylserine (PS) Exposed
on the Plasma Membrane
Apoptosis or necrosis was measured by simultaneous staining
with propidium iodide (PI) and Annexin V using the BD
PharminigenTM Annexin V–FITC apoptosis detection kit and
flow cytometry performed as described previously [23].
Statistical Analysis
Statistical comparisons were made using Student’s unpaired two
tailed T-tests in GraphPad Prism, version 4.0c. P,0.05 was
considered significant.
Results
Incorporation of BMAA into Human Proteins was Protein
Synthesis Dependent
Incubation of human MRC-5 fibroblasts with 3H-BMAA in
culture medium depleted in amino acids resulted in a time-
dependent increase in radiolabel in cell lysates (Figure 1A), a
proportion of which was associated with cell proteins (Figure 1B).
Co-incubation of MRC-5 cells with 3H-BMAA along with the
protein synthesis inhibitor CHX significantly reduced the amount
of radiolabel in the protein fraction (Figure 2). CHX inhibited
incorporation of the protein amino acid 3H-leucine into MRC-5
proteins to the same extent as 3H-BMAA (Figure 2) suggesting that
3H-BMAA was also incorporated into proteins by a protein
synthesis dependent mechanism. 3H-BMAA was also found to be
protein-associated after incubation with HUVEC and SH-SY5Y;
this process was again found to be protein synthesis dependent and
was inhibited by CHX (Figure 2).
To further examine the association between BMAA and cell
proteins, we examined the ability of a range of treatments to
release radiolabel from cell proteins. Radiolabeled cell proteins
were generated by incubating SH-SY5Y cells with 3H-BMAA for
24 hours. The radiolabel could not be removed from the isolated
cell proteins by incubation with a 100 fold molar excess of the
reducing agent DTT or by heating with the detergent SDS in the
presence of DTT (Figure 3). Release of radiolabel required
cleavage of peptide bonds by either acid hydrolysis or proteolytic
cleavage of peptide bonds with pronase (Figure 3).
BMAA Incorporation was Inhibited by L-serine
To determine if a specific protein amino acid was being
replaced by BMAA, we examined competition between all 20
protein amino acids and 3H-BMAA for incorporation into cell
proteins. We found that incorporation of 3H-BMAA into cell
proteins was inhibited in the presence of L-serine in a concentra-
tion-dependent manner (Figure 4A). D-serine, which cannot be
used in protein synthesis by mammalian cells, did not prevent
incorporation of 3H-BMAA into protein (Figure 4B). Incubation of
cells with 3H-BMAA in culture medium which contained all 20
protein amino acids (‘‘NONE’’) at 400 mM each, greatly reduced
the amount of radiolabel in the protein fraction relative to amino
acid-depleted culture conditions ‘‘ALL’’ (Figure 4C). When L-
serine alone was omitted from the amino acid mixture, ‘‘L-
SERINE’’, incorporation of BMAA into proteins significantly
increased (Figure 4C).
BMAA Released by Protein Hydrolysis was Positively
Identified with LC/MS/MS
To further confirm that BMAA was present in cell proteins, we
incubated MRC-5 cells with a range of concentrations of BMAA
and analyzed the hydrolyzed cell proteins by tandem mass
Misincorporation of L-BMAA into Proteins
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spectroscopy on a triple quadrupole LC/MS/MS. Retention
times, unique daughter ion (m/z 258), and ratios of m/z transitions
(m/z 459 to m/z 171 relative to m/z 459 to m/z 289 and m/z 459
to m/z 119 respectively) during collision-induced dissociation
matched those of an authenticated synthetic BMAA standard
(Figure 5A). Incubation of MRC-5 cells with increasing concen-
trations of BMAA, recovery via acid hydrolysis and triple
quadrupole LC/MS/MS analysis produced a linear recovery of
BMAA from the hydrolyzed proteins (r2 = 0.99, Figure 5B).
BMAA Induced Autofluorescence was Abrogated when
Co-incubated with L-serine
Autofluorescence, indicative of protein aggregation, developed
in cells incubated with 300 mM BMAA for 96 hours (Figure 6A)
and this could be abrogated by co-incubation with an equimolar
concentration of L-serine (Figure 6B). Autofluorescence was
localized to perinuclear and cytosolic regions of the cell but
appeared consistently across each well (Figure 6A). The absence of
changes in PI binding or in LDH release indicated that MRC-5
and SH-SY5Y cells were not undergoing necrotic cell death (data
not shown). However, apoptosis was present as indicated by
increased staining for Annexin V (Figure 6C). Apoptosis could be
Figure 1. Uptake and incorporation of 3H-BMAA into proteins
by MRC-5 cells. Panel A, uptake of radiolabel by cells was expressed
as disintegrations per minute (DPM) per mg of cell protein. Panel B,
radiolabel in the cell protein fraction was expressed as DPM per mg of
total cell protein. Values are mean +/2 SD for three independent
experiments (n = 3).
doi:10.1371/journal.pone.0075376.g001
Figure 2. Inhibition of incorporation of radiolabel into cell
protein by cycloheximide. MRC-5, HUVEC and SH-SY5Y cells were
incubated with 3H-BMAA with or without CHX (2 mg/ml). Cells proteins
were isolated and the amount of radiolabel present in proteins (DPM
per cell protein) determined and expressed as a percentage of control
where control treatments were designated 100%. Parallel cultures of
MRC-5 cells were incubated with 3H-leucine (41 nM) with or without
CHX and the effects of CHX similarly determined (open bars). Values are
mean +/2 SD for three independent experiments (n = 3). Radiolabel
incorporation in each cell type was compared with and without CHX
using Student’s two-tailed t-test (***P,0.001 ****P,0.0001).
doi:10.1371/journal.pone.0075376.g002
Figure 3. Recovery of radiolabel from cell proteins following
incubation of cells with 3H-BMAA. SH-SY5Y cells were incubated
with 3H-BMAA, cell proteins precipitated by TCA (10%) precipitation
and the amount of radiolabel released from proteins (i.e. not TCA
precipitable) after incubation with DTT or DTT and SDS quantified.
Percentage of radiolabel remaining in proteins following treatment is
expressed as a % of buffer alone. Cell proteins were also incubated with
pronase or HCl and the release of radiolabel quantified relative to that
of buffer alone (for Pronase) or water (for Acid). Values are mean +/2
SD, P,0.0001 using Student’s two-tailed t-test, three independent tests
(n = 3).
doi:10.1371/journal.pone.0075376.g003
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reduced by co-incubation with L-serine and also by CHX, which
suggests that apoptosis was triggered by BMAA incorporation into
proteins (Figure 6C).
Taken together these four different lines of evidence suggest that
incorporation of BMAA into cell proteins is a protein synthesis-
dependent process, which can be inhibited by L-serine.
Discussion
Protein misfolding, evidenced by the presence of aggregated and
tangled proteins manifested by neuroanatomical abnormalities
such as Bunina bodies, Lewy body inclusions, tauopathies, senile
plaques, and neurofibrillary tangles, is increasingly viewed as an
engine for disparate progressive neurodegenerative illnesses. Few
environmental agents have been identified that can induce protein
misfolding, subsequent protein aggregation, and apoptosis with the
notable exception of prions which are believed to be responsible
for Kuru, Creutzfeldt-Jakob Disease, or Bovine Spongiform
Encephalopathy. We here report that unusual amino acids can,
in a similar manner, induce protein misfolding through mis-
incorporation for one of the regular 20 canonical amino acids.
Motor neurons, as a special class of post-mitotic cells, are
particularly vulnerable to terminally aggregated proteins since they
are unable to reduce the burden of protein aggregates by
distributing them amongst daughter cells. This was evident in a
study in which neurodegeneration was the primary pathology in a
mouse with a minor translational proofreading defect [2].
Vulnerability may also be enhanced in motor neurons of
significant length where axonal transport may be compromised
by protein aggregates. In addition, adjacent cells may be impacted.
Luk et al. [24] found that injection of synthetic misfolded a-
synuclein into mouse brains cells results in a neurodegenerative
cascade of misfolded proteins in adjacent cells. If misfolded
proteins resulting from misincorporation of non-protein amino
acids can be transmissible within the brain through a prion-type
mechanism [25], it is possible that a neurodegenerative cascade
could be triggered.
Our finding that BMAA can be misincorporated for serine in
human proteins raises the possibility that such misincorporation
results in neurodegenerative illness. Phosphorylation of proteins
typically occurs on serine, threonine, tyrosine, and histidine
residues. Some serine sites such as tau serine residue 422 or TAR
DNA-binding protein 43 (TDP-43) serine residues 409/410 have
been identified as being key to neuropathologies [3,26]. BMAA
misincorporation at such sites may be particularly detrimental to
proper protein functioning. In vivo confirmation of BMAA-induced
protein misfolding and aggregation could be obtained if incipient
tauopathies, Bunina bodies, or other protein inclusions were to be
detected in non-human primates fed BMAA.
Exposure of human beings to BMAA has been documented on
Guam where the presence of protein-associated BMAA in cycad
flour was first observed by Polsky [27]. Protein-bound BMAA was
subsequently shown to be 50–100 times more abundant in flour
than the free form of BMAA [13,28]. Protein-associated BMAA
has since been found in cyanobacteria that are endosymbionts in
the coralloid roots of cycads, animals that forage on cycad seeds,
and post-mortem brain tissues of Chamorro villagers who died of
amyotrophic lateral sclerosis/Parkinsonism dementia complex
(ALS/PDC) as well as North American patients who died of
ALS and Alzheimer’s disease [13,29,30].
We found the misincorporation of BMAA into human proteins
to be a protein-synthesis dependent process in primary human
endothelial cells, and in human fibroblast and neuroblastoma cell
lines since it was significantly reduced when protein synthesis was
partially inhibited by the addition of CHX (Figure 2) or when the
concentration of the protein amino acid L-serine in the culture
medium was increased (Figure 4A). Further, D-serine, which
cannot be used in protein synthesis by mammalian cells, had no
effect on the incorporation of 3H-BMAA (Figure 4B). Previous
studies have demonstrated that acid hydrolysis was required to
Figure 4. Inhibition of incorporation or radiolabel into cell proteins by L-serine. Panel A, Incorporation of radiolabeled BMAA was inhibited
by L-serine in a concentration dependent manner. Panel B, D-serine (D-SER) had no significant impact on the incorporation of BMAA (NS, P=0.4419). L-
serine significantly inhibited the incorporation of BMAA compared to control cells (CTRL, ***P= 0.0002) and D-serine (D-SER, **P,0.01). Panel C, there
was a significantly (****P,0.001) greater incorporation of BMAA when all protein amino acids were omitted from the culture medium (ALL)
compared to when none were (NONE). When only L-serine was omitted (L-SERINE) incorporation was restored to approximately 80% (****P=0.0009).
Student’s two-tailed T-test, values are mean +/2 SD for three independent experiments (n = 3).
doi:10.1371/journal.pone.0075376.g004
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disassociate BMAA from proteins [13] and we here report that
BMAA can also be released from proteins by proteolytic cleavage
(Figure 3), providing further evidence that BMAA is peptide
bonded into the amino acid chain of proteins and peptides.
BMAA and other non-protein amino acids can mimic one of the
20 canonical amino acids and become mistakenly incorporated
into proteins [6–8,19,21,31]. A high level of fidelity in protein
synthesis is maintained because of the very low error rate on the
part of tRNA synthetases when selecting the correct protein amino
acid for esterification to the cognate tRNA [1]. tRNA synthetases
however are less efficient at discriminating against certain non-
protein amino acids of a similar, size, shape and charge to a
protein amino acid [31].
Aggregated proteins are characteristic of neurodegenerative
disease, hence they are sometimes known as ‘‘proteinopathies’’
owing to the deposition of aggregates of tau, a-synuclein,
huntingtin, superoxide dismutase-1, or TDP-43, which character-
ize such human neurodegenerative disorders as frontotemporal
degeneration, Parkinson’s disease, Lewy body disease, Hunting-
ton’s disease, and ALS. Our treatment of fibroblast cells with
BMAA resulted in the development of cellular autofluorescence
characteristic of protein aggregation (Figure 6A). We have
previously demonstrated that insertion of a non-protein amino
acid into a protein can result in protein misfolding and loss of
aqueous solubility [32] as well as the generation of in situ
autofluorescent material [21]. Incorporation of BMAA into
proteins in vivo might therefore be capable of generating misfolded
proteins that can ‘seed’ further protein aggregation in cells [33].
BMAA incorporation into proteins was found to induce
apoptosis in neuroblastoma cells in vitro, an effect previously
reported with other non-protein amino acids [23]. Incorporation
of BMAA into protein is also consistent with the dysregulation of
cellular protein homeostasis and ER stress reported by Okle [34].
Apoptosis and ER stress are inextricably linked to neurodegener-
ation and the gradual accumulation of BMAA-containing protein
aggregates in motor neurons could account for the chronic toxicity
reported following BMAA exposure which is preceded by a long
latency period [35].
Following a single i.v. bolus injection of 14C-labelled BMAA
into the femoral vein of rats, Xie [36] found that BMAA persisted
in the brain with a time course consistent with ‘trapping’ by
cerebral proteins. 1.5 hours after injection, free BMAA accounted
for more than 95% of BMAA in brain tissue but declined steadily
over the next 7 days while levels of protein-associated BMAA
remained relatively stable and accounted for around 80% of the
BMAA in the brain after 7 days. These studies are consistent with
BMAA being incorporated into proteins by protein synthesis and
an inability by neuronal cells to degrade these proteins. It is
feasible that protein-incorporated BMAA could accumulate in
specific regions of the brain as was evident in the study of Karlsson
[14] and this could relate to differences in the rate of uptake of free
Figure 5. Identification of BMAA in cell proteins using tandem
mass spectrometry. Panel A, a BMAA standard and a hydrolyzed
protein sample (from MRC-5 cells treated with 250 mM BMAA for 24
hours) were run on triple quadrupole LC/MS/MS. Retention times,
unique daughter ion (m/z 258), and ratios of m/z transitions during
collision-induced dissociation of the m/z 459 parent ion matched those
of an authenticated BMAA standard. Panel B, linear (r2 = 0.99012)
recovery of BMAA from the hydrolyzed proteins as determined by triple
quad LC/MS/MS. Values are mean +/2 SD from three independent
incubations (n = 3).
doi:10.1371/journal.pone.0075376.g005
Figure 6. Incubation with BMAA results in the formation of autofluorescent bodies and apoptotic changes in cells. Panel A,
Autofluorescence was observed in the cytosol and perinuclear regions of MRC-5 cells incubated with 300 mM BMAA. Panel B, autofluorescence was
reduced when cells were co-incubated with 300 mM L-serine. Cells were incubated in 6 well plates and showed consistent perinuclear and cytosolic
autofluorescence of varying degrees of intensity in BMAA treated cultures. The overall intensity of the signal was reduced when cells were co-
incubated with L-serine. Images are representative of at least 12 fields of view from triplicate cultures. Scale bar is 100 um. Panel C, incubation with
BMAA induced significant (**P= 0.0044) apoptosis in SH-SY5Y cells compared to control cells, which could be abrogated when co-incubated with L-
serine (***P= 0.0005) or CHX (**P=0.002). Student’s two-tailed T-test, values are mean + SD from three independent incubations (n = 3).
doi:10.1371/journal.pone.0075376.g006
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BMAA, the rate of protein turnover and the availability of L-serine
in different brain regions.
BMAA induces peptide changes in neonatal mice, with
demonstrable cognitive deficits in the adult mice [37] and this is
similar to deficits reported in honeybees [38]. Rats exposed to
BMAA produce neuropathologies similar to ALS [39]. Electron
microscopy of the spinal cord of BMAA-treated rats revealed a
number of changes that are consistent with incorporation of a non-
protein amino acid into proteins including elevated caspase 3 [23],
apoptotic changes [23], swollen cristae and general disorganisation
of mitochondria [40].
Whilst the acute effects of BMAA on neuronal cells [41,42] and
glial cells [43] have been clearly elucidated, epidemiological
studies of human health impacts of chronic BMAA exposure are
nascent. Our findings that BMAA can be misincorporated into
human proteins in vitro, with subsequent protein misfolding may
shed new light on reports of putative associations between human
exposure to cyanobacteria which produce BMAA and higher than
expected incidence rates of ALS. These associations have been
reported in residents of New England who lived near lakes subject
to frequent cyanobacterial blooms [44], among consumers of
shellfish in Chesapeake Bay [45], soldiers deployed to the Gulf
War between 1990–1991 [35], and in the Western Pacific ALS
foci including the indigenous people of Guam [13,29]. Proposed
longitudinal surveys [46] may provide a rigorous test of such
putative spatial associations.
The finding that L-serine can block the misincorporation of
BMAA into human proteins may prove useful in designing novel
therapies for ALS.
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